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Abstract
Despite a more than tenfold increase in opioid consumption in the past decades, many cancer patients still 
suffer pain. The current understanding of this situation is poorly understood. It is still possible that in some 
countries pain is still undertreated, but it is also possible that we do not appreciate opioid induced toxicity 
and other phenomena an/or our opioid prescribing needs to be refreshed. At the moment the only evidence 
based tool to deal with opioid toxicity is switching to another opioid. Other methods are also described, but 
are far less well evidenced. However, the effects after switching are short-lived and sometimes a number 
of switches are needed. In this article we discuss the rationale behind and the possibility of combining dif-
ferent opioids with each other. Opioids are all different and opioid receptors are heterogenous. There are 
data to suggest that widening the activity spectrum of opioids may be the way forward in order to decrease 
adverse effects and maintain analgesia. At the moment there are only some data on the interaction of 
fentanyl and morphine, morphine and oxycodone, and buprenorphine and morphine. These data suggest 
that we should investigate these problems vigorously and, instead of switching from one opioid to another, 
we may, in future, adopt the concept of a semi-switch, where the dose of the first opioid is decreased and 
a second opioid is added.
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Introduction and scope
Opioids remain the mainstay of the treatment 
of cancer pain. They are not the ideal analgesics but 
we do not have anything better. Interestingly, there 
has been a more than tenfold increase in opioid 
consumption in the past decades [1] but this has not 
resulted in an improvement in the pain experienced 
by patients. In fact, the prevalence of pain in cancer 
patients (treated and untreated) has remained con-
stant over the last 40 years [2]. While undoubtedly 
many patients with cancer pain are still under-treat-
ed, a growing number of patients may be treated 
too intensively and neurotoxicity is highly prevalent 
[3]. This neurotoxicity may include increased pain 
sensations, defined as opioid-induced hyperalgesia 
[4]. Neurotoxicity of opioids is probably due to 
the treatment of less opioid-sensitive pains with 
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opioids alone [5]. Failure to reduce the dose and 
add other, pain-mechanism-specific drugs, is still 
not appreciated in the primary care, where most of 
opioids are being prescribed.
There are a couple of mechanisms which still 
make us more and more aware of the shortcom-
ings of opioids and should prompt to investigation. 
First of all, patients with cancer now live longer 
and face new challenges resulting from severe, 
chronic, tumour-induced and tumour-unrelated 
pain and need opioid therapy for a longer time 
than previously [6]. Opioid tolerance and other 
long-term effects of opioids were simply ignored by 
clinicians as the patients did not, usually, live long 
enough to develop them [7]. In this light it is inter-
esting to note that the treatment of non-malignant 
pain using opioids has resulted in a new scale of 
observations and characterisations of long-term 
adverse effects [8]. Although opioids may be ef-
fective in the short term, their long-term efficacy 
is still debatable, probably because of their del-
eterious long-term effects and the development 
of tolerance [9]. New phenomena such as opioid 
neurotoxicity and cognitive impairment, including 
opioid-induced hyperalgesia as well as hypogonad-
ism and osteoporosis, have been described and their 
presence confirmed in cancer patients [4, 10–12]. It 
is too early to say how important these phenomena 
are in analgesia overall but it seems that the scene 
is dramatically changing and strategies aiming 
at limiting the opioid dose by combination with 
other drugs and non-pharmacological means have 
become more and more interesting.
In this article the question of whether the co-ad-
ministration of two opioids has the potential to 
increase analgesic activity with a concomitant re-
duction in adverse effects will be addressed. The 
co-prescribing of drugs other than opioids is beyond 
the scope of this article. 
In the past, when knowledge of opioids and 
the opioid receptors involved in pain transmis-
sion was limited, the general advice was to use 
one opioid at a time and to co-administer it with 
non-opioids such as paracetamol or NSAIDs [13, 
14]. Opioid combinations in clinical practice have 
never been recommended for general use and were 
considered by some to be a mark of poor clinical 
practice, as there was considerable fear that the 
total dose of opioids would markedly increase [15]. 
There was also a fear that the schemes would be 
too complicated and prone to errors by nurses, 
doctors and patients. “Keep it simple” was the 
advice [16, 17]. All effective analgesic opioids were 
seen as nearly identical and were invariably full 
μ-opioid-receptor agonists. The differences be-
tween opioids were unknown or simply ignored. 
This was also the reason why some “different” 
drugs such as buprenorphine are still unpopular 
despite their proven efficacy [18, 20].  
In the light of current knowledge there are several 
aspects which we need to take into account. We shall 
discuss them here in more detail: 
—  the differences between opioids; 
—  are all clinically efficacious opioid analge-
sics μ-agonists? What is the role of other opioid 
receptors in analgesia? 
—  opioid receptors may be heterogeneous and dif-
ferent drugs may react with different variants of 
these receptors; 
—  ultra-low doses of opioid receptor antago-
nists may increase opioid analgesia. 
After exploration of these four themes we shall 
review the existing evidence and make a plea for 
further investigations of opioid combinations as a po-
tential improvement in opioid therapy. 
Are opioids all the same 
or are there clinically relevant 
differences between them?  
Opioids may differ from each other in many 
ways [21]. They may have various physicochemical 
properties and because of these behave in differ-
ent ways in body fluids. For example, lipid-soluble 
drugs such as fentanyl and buprenorphine can be 
absorbed through the skin, will have a high volume 
of distribution and be preferentially metabolized by 
the liver. They will also readily cross the blood-brain 
barrier and act predominantly on the opioid recep-
tors localized in the central nervous system [22–24]. 
In contrast, more water-soluble morphine will be 
readily absorbed from the gastrointestinal tract, 
its volume of distribution will be much smaller 
and it will have problems crossing the blood-brain 
barrier. Morphine metabolites will be excreted in 
the urine as glucuronides. Morphine, because of 
its properties, will reach high concentrations outside 
the central nervous system. In this way it may also 
contribute to peripheral opioid analgesia [25]. The 
physicochemical properties of the drugs will also 
result in different pharmacokinetic behaviour and in 
longer or shorter stays of the drug in the body fluids. 
The physicochemical properties of drugs may result 
in their different affinities to opioid receptors and 
hence speed of association and dissociation from 
receptors. Buprenorphine is known to have the 
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highest affinity to opioid receptors and the longest 
time of association and dissociation with and from 
receptors [26]. While interacting with receptors, 
drugs may behave as full or partial agonists or like 
antagonists. Full agonists, for the same pharmaco-
dynamic effect, will occupy fewer receptors than 
partial agonists. In one study buprenorphine, a par-
tial agonist, occupied five times more opioid recep-
tors in comparison with dihydromorphine [26]. 
To make it even more complicated, opioids may 
differ in the way they influence opioid receptor 
metabolism after interacting with these receptors. 
Opioid receptors after interaction with most opi-
oids are phosphorilated and uncoupled from the 
G-proteins. Only morphine-activated μ-receptors fail 
to undergo arrestin-dependent uncoupling from 
G-proteins [27]. It is thought that this unique prop-
erty of morphine is related to its ability to develop 
tolerance. These differences are certainly clinically 
relevant but we still do not know how to use them 
to the benefit of patients. We do not know whether 
some opioids would be better at controlling inflam-
matory or neuropathic pain [13]. 
Are all clinically effective opioid 
analgesics μ-opioid-receptor agonists?
Morphine and fentanyl are seen as pure 
μ-opioid-receptor agonists, which means that their 
interactions with other than μ-opioid receptors are 
negligible. The same drugs are notorious for the 
development of tolerance. Oxycodone is probably, 
besides being a μ-opioid-receptor agonist, also 
a k-opioid-receptor agonist [28]; while buprenor-
phine, besides being a μ-opioid-receptor partial 
agonist, is also a k-opioid-receptor antagonist [29] 
and a potent agonist of the ORL1 receptor and in 
this way simulates the effect of pro-nociceptive dyn-
orphin [30, 31]. This latter effect is somewhat con-
troversial and counter-intuitive, as in a number of 
tests buprenorphine has been show to possess an-
ti-hyperalgesic properties [32]. Drugs may have 
metabolites or isomers acting on different recep-
tors and hence influence analgesia. Morphine’s me-
tabolite, morphine-6 b-glucuronide, is a potent opi-
oid agonist but probably acts on a different subset 
of μ-opioid receptors than the parent drug [33]. 
Methadone’s D-enantiomere has antagonistic prop-
erties at the NMDA channel receptors and hence 
may potentiate methadone’s analgesia [34–36]. 
However, this mechanism is still controversial as all 
components of methadone analgesia can be re-
versed by naloxone [37].  
Opioid receptors may be heteroge-
neous and different drugs may prefer-
entially react with different receptor 
variants
Opioid receptors can be classified as mu, kappa, 
delta and ORL1 [38]. Although μ-opioid receptors are 
the most important for analgesia, all other recep-
tors may influence analgesia directly or indirectly. 
Pure μ-opioid-receptor agonists are potent analge-
sics but show troublesome adverse effects, espe-
cially hyperalgesia and tolerance [39]. The simultane-
ous targeting of two or more receptor classes may 
offer an advantage. For example, targeting μ-opioid 
receptors and d-opioid receptors produces analgesia 
without the development of tolerance [39]. In addi-
tion, bivalent opioid ligands targeting both μ- and 
delta-opioid receptors produce potent antinocicep-
tion with less physical dependence and a marked 
reduction in the potential abuse liability relative 
to morphine. This could be achieved by designing 
new drugs which would act simultaneously on both 
types of receptor or the co-administration of two dif-
ferent drugs, each selective to one type of receptor. 
While the direct effect of μ-, d- and k-opioid-receptor 
activation may be analgesia, these receptors may 
differ in their effects on the modulation of the 
inflammation indirectly responsible for pain. Finley 
et al. have reviewed the evidence that activation of 
the k-opioid receptors induces an anti-inflammatory 
response through the down-regulation of cytokine, 
chemokine and chemokine-receptor expression, while 
activation of μ-opioid receptors favours a pro-inflam-
matory response [40]. Thus, although the activation 
of μ-opioid receptors by specific agonists may in the 
short term produce analgesia, this analgesia may be 
followed by hyperalgesia due to activation of the 
inflammatory pathway. 
To make the situation even more confusing, 
and individually unpredictable, we now know that 
opioid receptors come in many splice variants [41]. 
These splice variants may explain differences in 
responses to opioids. The prevalence of splice vari-
ants is still unknown but it is slowly emerging 
that it may differ not only from person to person, 
but different splice variants may coexist in one 
individual in different localizations in the central 
nervous system [42]. This may explain inter-indi-
vidual and somehow unpredictable differences in 
responses between, for example, morphine and 
oxycodone [43]. Morphine may have a high efficacy 
when interacting with one splice variant, while 
its metabolite, morphine-6 b-glucuronide, may 
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be most efficacious when another splice variant 
is present [33]. Diacetylmorphine (heroin) may also 
interact with some MOR-1 variants in better way 
than morphine does [44]. 
Opioid receptors and their splice variants may dif-
fer between the sexes [45] as the analgesic response 
to opioids and their toxicity between the sexes may 
also be different [46]. 
Ultra-low doses of opioid receptor 
antagonists may modulate opioid 
analgesia
Antagonists are thought to antagonize the 
effects of agonists and naloxone typically abol-
ishes analgesia evoked by full μ-opioid-receptor 
agonists. However, the same naloxone administered 
in an ultra-low dose may have a profoundly differ-
ent effect. Crain et al. first described how ultra-low 
doses of naloxone may selectively inhibit opioid 
receptors that are coupled not with the Gi and Go 
proteins, but with the Gs proteins [47]. This lat-
ter receptor-G-protein complex, seen as involving 
excitatory receptors, is more sensitive to naloxone. 
This may result in the abolition of hyperalgesia and 
the improvement of analgesia, which has been 
shown clinically in women undergoing hysterec-
tomy [48]. Apparently, many subsequent stud-
ies have shown either effects with a wide variation 
of “ultra-low” doses of naloxone or did not show 
this effect at all [49]. However, this research resulted 
in the patenting of a combination of oxycodone 
with the orally bio available antagonist naltrexone 
(Oxytrex®) and clinical studies with this drug are 
encouraging [50–51]. 
From the above discussion one thing may be 
obvious: a combination of opioids may, potentially, 
address a wider range of opioid receptors and their 
variants. We shall now review the existing data 
concerning the advantages and disadvantages of 
particular combinations of opioids.
Which pairs of opioids may have 
the potential to be more effective 
in the clinic?
Fentanyl and tramadol
In an open label study patients were random-
ized either to fentanyl alone or a fentanyl plus tra-
madol regime [52]. The addition of tramadol did 
not change anything in the level of analgesia or 
its adverse effects. However, it produced a marked 
reduction in the dose of fentanyl required to obtain 
an equivalent level of analgesia. The study was not 
geared to consider any other differences. The au-
thors conclude that the addition of tramadol also 
prevented patients from requiring steep fentanyl 
dose increases and developing tolerance. The au-
thors speculate that both drugs may have a syner-
gistic effect because of the different mechanism of 
action of the drugs. Besides the effect on serotonin 
and noradrenalin transport, tramadol may have an 
effect similar to that of local anaesthetics inhibiting 
voltage-gated sodium channels [53]. 
Fentanyl and morphine
Fentanyl’s role in the treatment of cancer pain 
seems well established. This drug is advocated by 
most comprehensive guidelines for both malignant 
and non-malignant pain [9, 54]. Numerous stud-
ies with this drug were conducted, although only in 
one controlled study was the analgesic effect of fen-
tanyl compared with a placebo [55]. Unfortunately, 
in this randomized trial with 138 patients fentanyl 
appears not to have been more effective than the 
placebo. The rescue medication was slightly higher 
in the placebo group receiving no other analge-
sics (NS). Nine patients from the fentanyl and 13 
patients from the placebo arm withdrew because 
of insufficient analgesia (NS). In the placebo group 
66% and in the fentanyl group 48% (NS) revealed 
a lack of efficacy against pain. The results were 
surely not encouraging, but in the pain world what 
counts is the comparison with the gold standard 
morphine, not a placebo. Here it is enough to show 
that the new drug is roughly equal to morphine 
and has no more or, even better, fewer adverse ef-
fects. An important randomized study assessing the 
safety and preference of fentanyl versus controlled 
morphine was published in 1997 by Ahmedzai et 
al. [56]. In this multi-centre study patients treated 
with fentanyl had significantly less constipation and 
less drowsiness, but more sleep disturbances and 
shorter periods of sleep than patients treated with 
morphine. Patients in the fentanyl phase needed ad-
ditional morphine “breakthrough” doses on 53.9% 
of the days, versus 41.5% of the days for the 
group of patients treated with controlled-release 
morphine (p = 0.0005). The doses of rescue mor-
phine were also higher in the fentanyl phase. For 
patients treated with fentanyl, 47.1% needed at 
least one increase of the dose while this was needed 
in only 27.4% of patients treated with controlled 
morphine. It must be pointed out, however, that 
the trial was funded by the pharmaceutical industry. 
What can be the interpretation of these data now, 
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15 years later? Fentanyl has a higher neurotoxic 
potential than morphine and may be a potent 
analgesic but also a hyperalgesic drug [57–59]. 
The addition of morphine as “rescue” medication 
is probably needed to counteract fentanyl-induced 
hyperalgesia. At the time of the 1997 study nobody 
had yet heard of opioid-induced hyperalgesia and 
neurotoxicity. For many patients morphine as a sec-
ond drug was not an “add-on” but a necessary 
step to prove or support the analgesic activity 
of fentanyl. Yet the pharmaceutical industry per-
suaded us that “the patients prefer to put a patch 
on than to swallow”. They forgot, however, that 
to achieve a good result more than half of the 
patients needed both to put a patch on and to 
swallow tablets/liquids. Probably much better re-
sults would have been achieved by a combination of 
fentanyl patches with controlled-release morphine. 
However, these kinds of studies are unthinkable 
for a competing industry. In the light of this, it 
is important to cite the study by Mercadante et 
al. [15]. In this study patients with rapidly escalat-
ing doses of opioids (100% in the last week) were 
randomized either to receive a second opioid or 
not. There were only five patients in the fentanyl 
group who received additional morphine and five 
patients in the morphine group who received ad-
ditional fentanyl. In general, in both arms of the 
study, the dose increment was halted and the pain 
scores were much improved, suggesting that the 
addition of the second opioid may influence the 
process of tolerance development. Other conclu-
sions were impossible because of the very low 
number of patients included. 
Morphine and oxycodone
Morphine and oxycodone clearly interact with 
a different sub-set of opioid receptors in the central 
nervous system. In particular, there is agreement 
that oxycodone is not only a μ-opioid-receptor 
agonist but also an agonist of k-opioid recep-
tors [60–62]. Intrathecal oxycodone has a limited 
analgesic potency in rats (2–7% in comparison with 
morphine) [63, 64] which could be translated into 
a clinical situation in having a much less potent 
effect when oxycodone is administered epidurally 
[65]. Oxycodone seems not to show a cross toler-
ance with morphine. Most of the patients who do 
not experience an analgesic effect from morphine, 
or experienced severe adverse effects, were able to 
obtain effective analgesia with oxycodone [43]. It 
is thus not surprising that the two drugs adminis-
tered together may have an interesting analgesic 
effect, as they have different mechanisms of action 
[62]. The administration of both morphine and 
oxycodone produces much more effective anal-
gesia with fewer CNS-related adverse effects in 
rats [66]. In humans this was tested in one study by 
Lauretti et al. [67] Twenty-six patients were treated 
in a double blind, randomized, cross over study of 
either 14 days of controlled-release morphine and 
14 days controlled-release oxycodone or the other 
way around. Patients were allowed to use imme-
diate-release morphine when the pain increased. 
Apparently, patients receiving a combination of 
controlled-release oxycodone and immediate-re-
lease morphine needed 38% less morphine than 
patients receiving a combination of two morphine 
preparations. Interestingly, patients receiving com-
bination oxycodone and morphine experienced 
significantly less nausea and vomiting. The au-
thors conclude that the interaction with both μ- and 
k-opioid receptors was beneficial for the analgesia 
and side effects profile. 
Buprenorphine and morphine
When buprenorphine was introduced some 30 
years ago there was a high degree of anxiety about 
the possibility that this drug may extract and replace 
morphine from its receptor [26, 68]. In the eyes of 
many professionals, this still meant that the only 
valuable analgesic effect of the full agonist would 
be lost. Subsequently several studies were conducted 
which showed something quite opposite. Buprenor-
phine administered systemically works perfectly to-
gether with epidural morphine from which, as we 
know, most of the infused drug  is also available 
systemically [69–71]. The responses are frequently 
supra-additive and the addition of buprenorphine to 
morphine does not increase the adverse effects. Mer-
cadante et al. [72] have more recently studied the use 
of IV infusions of morphine for breakthrough pain 
controlled mainly by transdermal buprenorphine. 
They also conclude that the responses were encour-
aging and frequently supra-additive. The conclusion 
from these data should be that the displacement of 
morphine has never been described in a clinical situ-
ation. Buprenorphine and morphine (and many other 
opioids) can be administered together without fear 
of negative interaction. The benefit of the combina-
tion is, however, far from being proved. There are 
no data of the interaction between buprenorphine 
and oxycodone. It is possible that the additive effect 
of oxycodone (a k-opioid-receptor agonist) could be 
lost because of buprenorphine’s k-opioid-receptor 
antagonism.
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Conclusions
Combinations of opioids have been poorly re-
searched because of the paradigm of using only one 
opioid at a time and because of a lack of interest 
in the subject from the pharmaceutical industry. 
This article shows that the addition of a second 
opioid is attractive, especially for abolishing the 
neuroexcitatory effects of the first. This is most 
probably the case with the combination of fen-
tanyl and morphine. The whole concept of “break-
through” medication should thus be re-investigated 
using this knowledge. The concept of a switch or 
opioid rotation from one opioid to another should 
be investigated according to Mercadante et al. 
[15], who introduced the notion of a semi-switch. 
In a patient with a rapid increase of tolerance and 
neuroexcitatory symptoms, instead of changing one 
opioid to another the dose of the first opioid should 
be decreased and a second opioid introduced. In 
this respect a combination of a lipophylic and a hy-
drophilic opioid (i.e., fentanyl-morphine, buprenor-
phine-morphine, methadone-morphine) are the 
most interesting. There are also some exciting data 
regarding combining morphine with oxycodone 
[66]. As oxycodone also acts on the k-receptors, it 
is a “natural” partner for μ-opioid-receptor agonists. 
Inhibiting both types of receptors may offer some 
advantages. What should be avoided at the moment 
is the combination of buprenorphine and oxyco-
done. There are no data on this combination at all, 
but buprenorphine is an antagonist of the k-opioid 
receptors and the greatest advantage of oxycodone 
k-opioid-receptor agonism would probably be lost 
using this combination. The combination of ago-
nists and ultra-low doses of antagonists is slowly 
coming to clinics, albeit simply because we still do 
not understand what exactly an “ultra-low” dose is. 
The final aspect, which we did not touch on here, 
is that of complexity of treatment. Taking two, or 
maybe in the future three, different opioids may 
make patients more vulnerable and mistakes would 
be more likely. However, it is perfectly possible in 
future to make combinations of two controlled-re-
lease drugs in one tablet. At the moment combina-
tions could be used as a last resort treatment in the 
case of rapidly developing tolerance and the loss of 
the analgesic potency of the drugs.
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